ClinicalTrials.gg
Active, not recruitingNCT02573415Updated Dec 5, 2025

Uterine Transplantation for the Treatment of Uterine Factor Infertility

An interventional study of Uterus Transplant in Primary Uterine Infertility, sponsored by The Cleveland Clinic. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-12-05.

Sponsored by The Cleveland Clinic · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 395 studies in Infertility with a site in United States — 62 open to participants now, 84 under way, 7 of them phase 3. Infertility · United States.

Planned enrollment
225th of 274
10 · median 84
Started
2015
with 21 others
No phase
168 of 395
24 open now
Primary completion
2026-12
later than 24 of 82 live
Registered
221st of 395
by date

Among the 395 studies in Infertility with a site in United States, this one is the 225th largest by planned enrollment of the 274 interventional ones that give a count, is one of 22 that started in 2015, is one of 168 with no phase, reaches primary completion later than 24 of the 82 other live ones, and was the 221st registered.

Infertility

2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

62 of the 395 studies in Infertility with a site in United States are open now. Recruiting first, the newest first:

57 more — sign in →

All 62 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 395 studies in Infertility with a site in United States, or all of them as a file.
02

Study summary

This feasibility study aims to enroll ten subjects who will undergo deceased donor uterine transplantation at Cleveland Clinic. We estimate that fifty to one hundred patients with uterine factor infertility will need to be screened to identify 10 appropriate subjects.

There are seven phases involved in this study: Primary and Secondary Screening, Medical Evaluation, IVF, Transplantation, Embryo Transfer, Pregnancy/Delivery and Follow up

Read the detailed description

Uterine factor infertility (UFI) is one of the few irreversible causes of female infertility. Until recently, no medical or surgical options have been available for women with this diagnosis. UFI is defined by the lack of a functional uterus; this condition can either be congenital (e.g. Rokitansky syndrome, where a woman is born without an intact uterus) or acquired (e.g. resulting from hysterectomy or damage to the uterus from procedures or infections).

Uterine infertility affects 3-5% of the female population. It is estimated that there are at least 50,000 women of reproductive age with uterine infertility in the United States. Existing options for women affected by UFI are limited to adoption or maternal surrogacy. Surrogacy involves harvesting eggs from the UFI patient and fertilizing these eggs in a lab with the intention of implanting fertilized embryos into a third party who will carry the pregnancy. Adoption and surrogacy are considered acceptable options for many women with UFI. For others, due to social, ethical, cultural and/or religious reasons, these options are not permissible. In many countries around the world, maternal surrogacy is illegal, leaving no option for UFI patients to conceive a biological child.

Recently, uterine transplantation has been proposed as an alternative method of treating UFI. Uterine transplantation is intended as a life enhancing procedure, not a life saving procedure, and is considered to be similar to transplants of the face, extremities and pancreas. Interestingly, uterine transplantation is considered an "ephemeral" transplant, and is not intended to last for the duration of the life of the recipient. The transplant is maintained for only as long as is necessary to produce one or two offspring for the patient.

The need for novel approaches to UFI is clear and exciting work from a team of investigators in Sweden has finally demonstrated this year that uterine transplantation can result in the successful delivery of healthy infants with minimal risk to the mother. After careful collaboration with this Swedish group, we now aim to bring the first uterine transplantation protocol to the United States using a multidisciplinary team of investigators from within the Cleveland Clinic.

There have been 11 uterine transplants performed in humans worldwide. The first uterine transplant was performed in Saudi Arabia in 2000. The living-donor graft survived for 3 months and was subsequently removed due to graft failure. The failure of the graft was attributed to thrombosis (blood clots affecting the circulation to the organ). Pregnancy was never attempted using the transplanted uterus prior to it being removed.

This year, Brännström M. et al. published their experience with the first clinical trial of human uterine transplantation in a series of 9 women. The clinical trial, based in Sweden, began in 2012 under Institutional Review Board (IRB) approval from the University of Gothenburg. The nine women in the study group received uteri from living donors and the report, published in Fertility and Sterility in May 2014, described that seven out of the nine transplants were viable after six months of follow up. Nonviability of the two grafts was reportedly due to uterine artery thrombosis. In most cases, donors were the recipient's mother. Eight of the recipients had Rokitansky syndrome. One recipient had undergone a hysterectomy for cervical cancer. There were no immediate perioperative complications and all patients with successful grafts began to have spontaneous menstrual periods within a few months of transplantation. Mild rejection appeared to be treatable with steroids. All recipients had 10 viable embryos produced by in vitro fertilization performed prior to uterine transplantation. Those embryos were then transferred into the transplanted uterus to achieve pregnancy. This research has now resulted in the first published report of a human live birth from uterine transplantation.

In the Gothenburg experience, the donor operation consisted of a hysterectomy including the uterine arteries and veins with the branches of the internal iliac artery and vein and vault of vagina. The first segment of the ovarian veins caudad to the ovaries (in order to protect their outflow) was also included. The explanted uterus was perfused with chilled University of Wisconsin (UW) solution and prepared for implantation. The implantation was achieved by anastomosis into the iliac vessels bilaterally, in some cases the donor ovarian veins where included. The vault of the donor vagina was anastomosed into the existing vagina or neovagina. Immunosuppression following uterine transplantation included induction with thymoglobulin and maintenance with tacrolimus, mycophenolate mofetil and oral steroids. Mycophenolate mofetil was discontinued before pregnancy attempts as it is contraindicated in pregnancy. This immunosuppression regimen is similar to the regimen proven effective in kidney transplantation, another solid organ graft.

Dr. Andreas Tzakis has been working closely with the Gothenburg group through both early animal models as well as the recent clinical trial in humans. Below is a summary of this group's published relevant findings:

  1. Two grafts were lost (one soon after transplant and the other 4 months later) due to uterine artery thrombosis.
  2. One donor had a surgical complication, her ureter was injured during removal of the uterus, and she required a late ureteral reimplantation due to ischemic damage of her ureter
  3. Five recipients developed mild rejection of the graft. This was detected by cervical biopsy and was treated successfully with steroids in all cases.
  4. Menstruation occurred regularly in all seven subjects with a successful transplant within a few months of transplantation.
  5. One documented subject had one live birth by Cesarean section; this pregnancy was complicated by preeclampsia (high blood pressure of pregnancy) at 31.5 weeks gestation

4. Pregnancy after Solid Organ Transplantation

Since only one live birth in human uterine transplant recipients has been reported, the pregnancy risks are not firmly established; however pregnancies and deliveries after uterine transplantation of healthy offspring have been accomplished in small and large animals (mice, rats, sheep, nonhuman primates). In addition, pregnancy after other solid organ transplants in humans is well documented.

The use of immunosuppressive medication is well studied in pregnancy after solid organ transplantation as well as in women with certain rheumatologic conditions and inflammatory bowel disease. Tacrolimus and cyclosporine are among the most widely used in pregnancy. Birth defects with cyclosporine or tacrolimus occur at an incidence of 4-5% which is no different than the general population. Cyclosporine is associated with low birth weight but does not appear to impact long term outcomes including intelligence quotient (IQ). Mycophenolate mofetil (MMF) is associated with a specific pattern of birth defects including facial malformations, finger abnormalities and heart defects. This medication should not be used in the first trimester of pregnancy. Azathioprine does not cause birth defects. Corticosteroids are considered safe however high doses can increase the risk of premature rupture of membranes. Immunosuppression is also noticed in infants exposed to these medications during pregnancy including low immunoglobulin levels and lymphocyte counts. Most of these deficits seem to normalize by the sixth month of life, with no noted impact on the infants' health.

Renal transplant is the most common solid organ transplant after which pregnancy has been reported. In these women over 90% achieve successful pregnancy outcomes after the first trimester. Pregnancy risks include low birth weight, preterm delivery and preeclampsia. It has consistently been shown that pregnancy does not adversely affect the graft function or survival.

The most frequent maternal complication in this patient population is pregnancy induced hypertension. Management of such pregnancy complications uterine transplant recipients should follow standard obstetric guidelines.

Prematurity is the main fetal complication, which affects nearly 40% of live births. The mean reported gestational age at delivery is 36.5 weeks, while the mean birth weight is approximately 14% less than general population (6 lb 5 oz vs 7 lb 4 oz). Other fetal complications that have been observed include intrauterine growth restriction (approximately 20%), prenatal infections, and birth defects.

Over 400 pregnancies after liver transplantation have been reported. Similar risks are reported in these women including preeclampsia preterm birth and low birth weight. Less data is available from women who have undergone less common transplants. Kidney-pancreas transplant is associated with a higher complication rates. Hypertension is reported and 75% in addition there is a 55% risk of infection and 68% risk of low birth weight. These studies are limited by lack of consideration of the original disease of the organ recipient or the functional status of the transplanted organ. Women undergoing uterine transplantation will have no significant preexisting medical conditions unlike women undergoing other solid organ transplantations. Both these elements are likely to have an influence on the incidence of complications of the pregnancy and have not been included in previous large analyses.

According to The American Society of Transplantation, pregnancy is allowable in renal organ transplantation one year after transplantation if there has been no signs of rejection, the transplanted organ has adequate function, there is no active infection (particularly cytomegalovirus infection) and the immunosuppression dose has been stable.

Waiting one year after the transplantation prior to conception decreases the risk of acute rejection and infection. During the pregnancy it is important to monitor blood pressure and treat hypertension diligently, maintain strict glycemic control, monitor for signs of infection, and assess maternal levels of immunosuppressive medications more frequently.

03

Conditions studied

  • Primary Uterine Infertility

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must meet criteria for uterine factor infertility

    1. Prior hysterectomy
    2. Congenital absence or malformation of the uterus preventing pregnancy c, Infertility due to uterine damage from prior injury or infection
  2. Must be between the ages of 21-45 and the embryos must have been produced between the age of 21-39. (age at the time the embryos are produced, not current age)
  3. Must be willing to undergo a psychiatric and social work pre-transplant evaluation
  4. Must be willing to undergo general anesthesia, in vitro fertilization, major gynecologic surgery, pregnancy with potential high risk complications, cesarean delivery and eventual hysterectomy to remove the graft
  5. Must be willing and able to receive potent medications and must be able to follow standard infection prophylaxis protocols
  6. Must be willing to receive standard vaccinations such as influenza, pneumococcus, human papillomavirus (HPV) and
  7. Must be willing and able to sign and follow all outlined procedures and recommendations in the protocol

Exclusion criteria

Exclusion Criteria:

  1. History of hypertension, diabetes, or significant heart, liver, kidney or central nervous system disease
  2. Any medical diagnosis placing the subject at high risk of surgical complications based on the transplant team's review of medical history.
  3. Current smoker (smoking cessation must have occurred 3 months prior to enrollment)
  4. History of prior except for cervical cancer in stage 1a or 1b after 3 years.
  5. , mycobacteria, (Hepatitis risk is for those with hepatitis B (HB) surface and/or core antigen and/or hepatitis B virus (HBV) DNA positive. Thos that are HB core antibody positive are at minimal risk and everyone else is not at risk), or .
  6. Presence of active documented systemic infection or recent systemic infection within the past three months
  7. Chemical and/or alcohol dependency or abuse
  8. Presence of low lying pelvic kidney(s). Pelvic and horse shoe kidneys are common in the Rokitansky syndrome, and occur with a frequency as high as 30-40%. These abnormalities are usually known to subjects as part of their Mullerian agenesis diagnosis. If the patient is unsure about the status of their kidneys, the performance of a renal ultrasound is considered standard of care. These patients need to be informed of any kidney abnormalities, as they are frequently associated with kidney stones or obstructive kidney disease.
  9. greater than 30 kg/m2
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Uterus Transplantation

    Women will undergo deceased donor uterine transplantation after IVF.

    Procedure: Uterus Transplant

Interventions

  • ProcedureUterus Transplant

    transplant of a deceased donor uterus.

06

What researchers measure

Primary outcomes

  1. Number of successful live births after uterus transplant and IVF

    Full term birth by cesarian section after IVF followed by uterus transplant

    Time frame: 2 years after transplantation

07

Study locations

1 site
08

References and documents

Publications

  • Johannesson L, Humphries LA, Porrett PM, Testa G, Anderson S, Walter JR, Rush M, Ferrando CA, O'Neill K, Richards EG. Classification and treatment of vaginal strictures at the donor-recipient anastomosis after uterus transplant. Fertil Steril. 2024 Sep;122(3):525-534. doi: 10.1016/j.fertnstert.2024.04.019. Epub 2024 Apr 16. PubMed 38636770 ↗
  • Walter JR, Johannesson L, Falcone T, Putnam JM, Testa G, Richards EG, O'Neill KE. In vitro fertilization practice in patients with absolute uterine factor undergoing uterus transplant in the United States. Fertil Steril. 2024 Sep;122(3):397-405. doi: 10.1016/j.fertnstert.2024.04.017. Epub 2024 Apr 15. PubMed 38631504 ↗
  • Richards EG, Agatisa PK, Davis AC, Flyckt R, Mabel H, Falcone T, Tzakis A, Farrell RM. Framing the diagnosis and treatment of absolute uterine factor infertility: Insights from in-depth interviews with uterus transplant trial participants. AJOB Empir Bioeth. 2019 Jan-Mar;10(1):23-35. doi: 10.1080/23294515.2019.1572672. Epub 2019 Mar 11. PubMed 30855220 ↗
  • Arian SE, Flyckt RL, Farrell RM, Falcone T, Tzakis AG. Characterizing women with interest in uterine transplant clinical trials in the United States: who seeks information on this experimental treatment? Am J Obstet Gynecol. 2017 Feb;216(2):190-191. doi: 10.1016/j.ajog.2016.11.1028. Epub 2016 Nov 16. No abstract available. PubMed 27865979 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2015, a primary completion of Dec 2026 and a completion of Mar 2027. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2015
First posted
Oct 9, 2015
Start
Oct 2015
Primary completionEst.
Dec 2026
CompletionEst.
Mar 2027
Last update
Dec 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02573415
Responsible party
Michelle Kuznicki (Staff Physician, The Cleveland Clinic) — Principal investigator
First posted
Oct 9, 2015
Start date
Oct 2015
Primary completion
Dec 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Dec 5, 2025

Study contacts

Michelle Kuznicki, MD
principal investigator · The Cleveland Clinic

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion